

Nerea Varo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3526884/nerea-varo-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 papers	4,082 citations	36 h-index	63 g-index
81 ext. papers	4,423 ext. citations	6.5 avg, IF	4.57 L-index

#	Paper	IF	Citations
66	Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy.. <i>Oncolmunology</i> , 2022 , 11, 2070337	7.2	1
65	Prenatal and childhood exposure to air pollution and traffic and the risk of liver injury in European children. <i>Environmental Epidemiology</i> , 2021 , 5, e153	0.2	0
64	A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer. <i>Translational Research</i> , 2021 , 233, 77-91	11	3
63	Prenatal Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children. <i>Hepatology</i> , 2020 , 72, 1758-1770	11.2	27
62	Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD. <i>International Journal of COPD</i> , 2020 , 15, 1823-1829	3	0
61	Trabecular bone score and bone remodelling markers identify perimenopausal women at high risk of bone loss. <i>Clinical Endocrinology</i> , 2019 , 91, 391-399	3.4	7
60	Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1539-1545	5.9	40
59	Trabecular bone score in active or former smokers with and without COPD. <i>PLoS ONE</i> , 2019 , 14, e0209777	3.7	3
58	Liquid Biopsy: From Basic Research to Clinical Practice. <i>Advances in Clinical Chemistry</i> , 2018 , 83, 73-119	5.8	37
57	Hypoglycemic Syndrome without Hyperinsulinemia. A Diagnostic Challenge. <i>Endocrine Pathology</i> , 2016 , 27, 50-4	4.2	5
56	Role of HIF1A, VEGFA and VEGFR2 SNPs in the Susceptibility and Progression of COPD in a Spanish Population. <i>PLoS ONE</i> , 2016 , 11, e0154998	3.7	9
55	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. <i>International Journal of Cardiology</i> , 2015 , 185, 177-85	3.2	21
54	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. <i>Liver International</i> , 2015 , 35, 1590-6	7.9	37
53	Osteoprotegerin in Cardiometabolic Disorders. <i>International Journal of Endocrinology</i> , 2015 , 2015, 564934	3.7	54
52	IL-8 gene variants are associated with lung function decline and multidimensional BODE index in COPD patients but not with disease susceptibility: a validation study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 55-61	2	11
51	Comparison of Intravenous and Oral Hydration in the Prevention of Contrast-Induced Acute Kidney Injury in Low-Risk Patients: A Randomized Trial. <i>Nephron</i> , 2015 , 131, 51-8	3.3	12
50	Coinhibitory suppression of T cell activation by CD40 protects against obesity and adipose tissue inflammation in mice. <i>Circulation</i> , 2014 , 129, 2414-25	16.7	48

49	Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification. <i>Clinical Biochemistry</i> , 2014 , 47, 272-8	3.5	34
48	Influence of pre-analytical and analytical factors on osteoprotegerin measurements. <i>Clinical Biochemistry</i> , 2014 , 47, 1279-85	3.5	7
47	Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. <i>Journal of Hypertension</i> , 2013 , 31, 587-94	1.9	12
46	Traditional and novel bone remodeling markers in premenopausal and postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1740-8	5.6	23
45	Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. <i>Respiratory Research</i> , 2012 , 13, 71	7.3	56
44	The influence of obesity on the assessment of carotid intima-media thickness. <i>Journal of Clinical Ultrasound</i> , 2012 , 40, 479-85	1	6
43	Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 1477-87	9.4	46
42	Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. <i>Critical Care</i> , 2011 , 15, R97	10.8	43
41	Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study. <i>PLoS ONE</i> , 2011 , 6, e16021	3.7	38
40	TNFA-863 polymorphism is associated with a reduced risk of chronic obstructive pulmonary disease: a replication study. <i>BMC Medical Genetics</i> , 2011 , 12, 132	2.1	10
39	Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. <i>Circulation</i> , 2010 , 121, 2033-44	16.7	54
38	TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation. <i>Circulation Research</i> , 2010 , 107, 757-66	15.7	43
37	Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010 , 298, E1072-7	6	32
36	Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. <i>Journal of Hypertension</i> , 2010 , 28, 2219-26	1.9	5
35	CD40L induces inflammation and adipogenesis in adipose cells--a potential link between metabolic and cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 788-96	7	52
34	Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans. <i>PLoS ONE</i> , 2010 , 5, e11589	3.7	20
33	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. <i>Clinical Science</i> , 2009 , 116, 233-40	6.5	8
32	Identification of a locus modulating serum C-reactive protein levels on chromosome 5p15. <i>Atherosclerosis</i> , 2008 , 196, 863-70	3.1	8

31	Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 294, E52-60	6	60
30	Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. <i>Advances in Clinical Chemistry</i> , 2008 , 45, 155-97	5.8	33
29	The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2319-27	5.6	30
28	Advantage of salivary cortisol measurements in the diagnosis of glucocorticoid related disorders. <i>Clinical Biochemistry</i> , 2008 , 41, 688-92	3.5	63
27	Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?. <i>Cardiovascular Research</i> , 2007 , 75, 536-45	9.9	28
26	Variation in blood levels of inflammatory markers related and unrelated to smoking cessation in women. <i>Preventive Cardiology</i> , 2007 , 10, 68-75		10
25	C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1369-78	15.1	147
24	Family history of diabetes is a major determinant of endothelial function. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2456-61	15.1	71
23	Influence of pre-analytical and analytical factors on soluble CD40L measurements. <i>Clinical Science</i> , 2006 , 111, 341-7	6.5	50
22	Analytical interference of hydroxyurea in the determination of urea, uric acid, and lactic acid. <i>Analytical Biochemistry</i> , 2006 , 357, 147-9	3.1	4
21	Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk. <i>American Heart Journal</i> , 2006 , 151, 367.e7-367.e16	4.9	52
20	Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 2192-6	9.4	84
19	Neurohormones and Cytokines in Heart Failure. Correlation With Coronary Flow Reserve. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2005 , 58, 1273-1277	0.7	1
18	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. <i>Journal of Hypertension</i> , 2005 , 23, 625-32	1.9	60
17	Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. <i>Journal of Hypertension</i> , 2005 , 23, 2297-304	1.9	36
16	Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. <i>Diabetes and Vascular Disease Research</i> , 2005 , 2, 81-7	3.3	41
15	Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. <i>Circulation</i> , 2004 , 110, 1953-9	16.7	70
14	Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003 , 23, e11-4	9.4	52

13	Soluble CD40L: risk prediction after acute coronary syndromes. <i>Circulation</i> , 2003 , 108, 1049-52	16.7	330
12	Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. <i>Circulation</i> , 2003 , 107, 2664-9	16.7	174
11	Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. <i>Hypertension</i> , 2002 , 39, 923-8	8.5	63
10	Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. <i>Circulation</i> , 2002 , 106, 2888-93	16.7	145
9	Soluble CD40L and cardiovascular risk in women. <i>Circulation</i> , 2001 , 104, 2266-8	16.7	396
8	Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. <i>Circulation</i> , 2001 , 104, 286-91	16.7	214
7	Biochemical assessment of myocardial fibrosis in hypertensive heart disease. <i>Hypertension</i> , 2001 , 38, 1222-6	8.5	143
6	Characterisation with stable isotopes of the presence of a lag phase in the gastric emptying of liquids. <i>European Journal of Nutrition</i> , 2000 , 39, 224-8	5.2	24
5	Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. <i>Circulation</i> , 2000 , 101, 1729-35	16.7	297
4	Transforming growth factor beta in hypertensives with cardiorenal damage. <i>Hypertension</i> , 2000 , 36, 517-23	8.5	111
3	Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. <i>Hypertension</i> , 2000 , 35, 1197-202	8.5	115
2	Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 1999 , 17, 107-14	1.9	92
1	Abnormalities of the extracellular degradation of collagen type I in essential hypertension. <i>Circulation</i> , 1998 , 98, 535-40	16.7	272